Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Response of NAFLD Patients to Mediterranean Diet

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03203486
Recruitment Status : Completed
First Posted : June 29, 2017
Last Update Posted : June 29, 2017
Sponsor:
Collaborators:
National and Kapodistrian University of Athens
Greek Secretariat for Research and Technology
Information provided by (Responsible Party):
Andriana C Kaliora, Harokopio University

Brief Summary:
The effects of Mediterranean Diet (MedDiet) on clinical, biochemical and inflammatory profile in NAFLD patients with simple steatosis. Potential associations of single nucleotide polymorphisms to diet composition and patients' profile were also investigated.

Condition or disease Intervention/treatment Phase
NAFLD Steatosis of Liver Other: Mediterranean Diet Not Applicable

Detailed Description:
Diet is a modifiable key factor targeted in prevention and management of non-alcoholic fatty liver disease (NAFLD). The aim of the study is to investigate the effect of Mediterranean Diet (MedDiet) on clinical, biochemical and inflammatory profile in NAFLD patients with simple steatosis. Potential associations of single nucleotide polymorphisms to diet composition and patients' profile are investigated. In this non-randomised, open-label study, 44 untreated NAFLD patients with non significant fibrosis receive nutritional counsel to increase adherence to MedDiet. Adherence to MedDiet is estimated with MedDietScore. Furthermore, genotyping of STAT3 rs2293152 and GCKR rs1260326 single nucleotide polymorphisms takes place.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: non-randomised, open-label study
Masking: None (Open Label)
Primary Purpose: Other
Official Title: The Effectiveness of a Mediterranean Diet Intervention in NAFLD Clinical Course
Actual Study Start Date : April 2014
Actual Primary Completion Date : July 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Meditteranean Diet
NAFLD patients attended appointments with experienced dieticians to receive nutritional guidance based on a traditional Mediterranean Diet for 6 months.
Other: Mediterranean Diet
Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.




Primary Outcome Measures :
  1. Regulation of hepatic steatosis [ Time Frame: Change from Baseline to 6 months ]
    A decrease in liver fat


Secondary Outcome Measures :
  1. Adherence to MedDiet [ Time Frame: Change from Baseline to 6 months ]
    Increase in MedDietScore

  2. Regulation of visfatin [ Time Frame: Change from Baseline to 6 months ]
    Decrease in visfatin levels

  3. Regulation of oxLDL [ Time Frame: Change from Baseline to 6 months ]
    Decrease in oxLDL levels

  4. Association of single nucleotide polymorphisms to response to dietary treatment [ Time Frame: Change from Baseline to 6 months ]
    Decrease in visfatin in carriers of the risk allele



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • men and women >18y of age, no change in body weight (BW) for the last 6 months prior to the trial and body mass index (BMI) >25 kg/m2.

Exclusion Criteria:

  • the presence of chronic viral hepatitis, the presence of congenital or acquired liver disease, the history of prior exposure to hepatotoxic drugs, the evidence of hepatic cirrhosis, ultrasonography values less than 1Hz, bariatric surgery, daily consumption of ethanol more than 20g for women and more than 30g for men for over 6 months during the last 5 years, any medication effective on fatty liver disease introduced <6 months prior to or during the trial, the co-presence of a life-threatening disease, psychiatric disorders impairing the patient's ability to provide written informed consent, age>65 years, pregnant or lactating women, subjects supplemented with omega-3 polyunsaturated fatty acids, probiotics/synbiotics, antioxidant vitamins and/or phytochemicals, any planned, structured and repetitive physical activity. Patients with any medication change during the trial were excluded from analysis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03203486


Sponsors and Collaborators
Harokopio University
National and Kapodistrian University of Athens
Greek Secretariat for Research and Technology
Investigators
Layout table for investigator information
Principal Investigator: Andriana C Kaliora, PhD Harokopio University of Athens
Layout table for additonal information
Responsible Party: Andriana C Kaliora, Assistant Professor, Human Nutrition and Foods, Harokopio University
ClinicalTrials.gov Identifier: NCT03203486    
Other Study ID Numbers: 09-ΣΥΝ-12-890
First Posted: June 29, 2017    Key Record Dates
Last Update Posted: June 29, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Andriana C Kaliora, Harokopio University:
NAFLD
no fibrosis
Mediterranean diet
STAT3
GCKR
visfatin
oxidized LDL
fasting glucose
inflammation
Additional relevant MeSH terms:
Layout table for MeSH terms
Non-alcoholic Fatty Liver Disease
Fatty Liver
Liver Diseases
Digestive System Diseases